Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott–Aldrich syndrome

[1]  A. Galy,et al.  WAS Promoter-Driven Lentiviral Vectors Mimic Closely the Lopsided WASP Expression during Megakaryocytic Differentiation , 2020, Molecular therapy. Methods & clinical development.

[2]  L. Notarangelo,et al.  Excellent Outcomes Following Hematopoietic Cell Transplantation for Wiskott-Aldrich Syndrome: A PIDTC Report. , 2020, Blood.

[3]  F. Bushman,et al.  Clonal tracking in gene therapy patients reveals a diversity of human hematopoietic differentiation programs. , 2020, Blood.

[4]  C. Pignata,et al.  Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome , 2019, The Journal of allergy and clinical immunology.

[5]  K. Stamatopoulos,et al.  Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study , 2019, Leukemia.

[6]  F. Bushman,et al.  Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges , 2019, Nature Reviews Drug Discovery.

[7]  L. Biasco,et al.  Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study , 2019, The Lancet. Haematology.

[8]  A. Worth,et al.  Bleeding and splenectomy in Wiskott-Aldrich syndrome: A single-centre experience. , 2019, The journal of allergy and clinical immunology. In practice.

[9]  L. Notarangelo,et al.  Autonomous role of Wiskott‐Aldrich syndrome platelet deficiency in inducing autoimmunity and inflammation , 2018, The Journal of allergy and clinical immunology.

[10]  G. Lucchini,et al.  One hundred percent survival after transplantation of 34 patients with Wiskott-Aldrich syndrome over 20 years. , 2018, The Journal of allergy and clinical immunology.

[11]  S. Kozlovskaya,et al.  A Conditioning Regimen with Plerixafor Is Safe and Improves the Outcome of TCRαβ+ and CD19+ Cell-Depleted Stem Cell Transplantation in Patients with Wiskott-Aldrich Syndrome. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  D. Covas,et al.  Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients. , 2018, Blood advances.

[13]  Javier Rey-Barroso,et al.  The Wiskott-Aldrich Syndrome Protein Contributes to the Assembly of the LFA-1 Nanocluster Belt at the Lytic Synapse. , 2018, Cell reports.

[14]  F. Bushman,et al.  Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult. , 2017, Blood.

[15]  Kyle Bittinger,et al.  INSPIIRED: A Pipeline for Quantitative Analysis of Sites of New DNA Integration in Cellular Genomes , 2016, Molecular therapy. Methods & clinical development.

[16]  Kyle Bittinger,et al.  INSPIIRED: Quantification and Visualization Tools for Analyzing Integration Site Distributions , 2016, Molecular therapy. Methods & clinical development.

[17]  D. Liggitt,et al.  Safe and Effective Gene Therapy for Murine Wiskott-Aldrich Syndrome Using an Insulated Lentiviral Vector , 2016, Molecular therapy. Methods & clinical development.

[18]  F. Candotti.  Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome , 2017, Journal of Clinical Immunology.

[19]  E. Meffre,et al.  Lentiviral-mediated gene therapy restores B cell tolerance in Wiskott-Aldrich syndrome patients. , 2015, The Journal of clinical investigation.

[20]  M. van der Burg,et al.  B-cell reconstitution after lentiviral vector–mediated gene therapy in patients with Wiskott-Aldrich syndrome , 2015, The Journal of allergy and clinical immunology.

[21]  Frederic D Bushman,et al.  Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. , 2015, JAMA.

[22]  Michael Rothe,et al.  Gene Therapy for Wiskott-Aldrich Syndrome—Long-Term Efficacy and Genotoxicity , 2014, Science Translational Medicine.

[23]  Luca Biasco,et al.  Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome , 2013, Science.

[24]  W. Vainchenker,et al.  Wiskott-Aldrich syndrome protein-deficient hematopoietic cells can be efficiently mobilized by granulocyte colony-stimulating factor , 2013, Haematologica.

[25]  A. Fischer,et al.  Characteristics and outcome of early-onset, severe forms of Wiskott-Aldrich syndrome. , 2013, Blood.

[26]  Habib Ramezani,et al.  A Note on the Normalized Definition of Shannon’s Diversity Index in Landscape Pattern Analysis , 2012 .

[27]  H. Ochs,et al.  Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome. , 2012, Blood.

[28]  S. Davies,et al.  Outcomes following hematopoietic cell transplantation for Wiskott–Aldrich syndrome , 2012, Bone Marrow Transplantation.

[29]  G. Driessen,et al.  Paediatric Reference Values for the Peripheral T cell Compartment , 2011, Scandinavian journal of immunology.

[30]  A. Fischer,et al.  Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. , 2011, Blood.

[31]  L. Notarangelo,et al.  Clinical spectrum, pathophysiology and treatment of the Wiskott–Aldrich syndrome , 2011, Current opinion in hematology.

[32]  M. Bryckaert,et al.  Platelet JNK1 is involved in secretion and thrombus formation. , 2010, Blood.

[33]  L. Muul,et al.  Somatic mosaicism in the Wiskott-Aldrich syndrome: molecular and functional characterization of genotypic revertants. , 2010, Clinical immunology.

[34]  S. Burns,et al.  WASP: a key immunological multitasker , 2010, Nature Reviews Immunology.

[35]  C. Doglioni,et al.  Revertant T lymphocytes in a patient with Wiskott-Aldrich syndrome: analysis of function and distribution in lymphoid organs. , 2010, The Journal of allergy and clinical immunology.

[36]  L. Notarangelo,et al.  WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function. , 2008, Blood.

[37]  A. Fischer,et al.  Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. , 2008, Blood.

[38]  J. Halterman,et al.  Neutropenia in pediatric practice. , 2008, Pediatrics in review.

[39]  W. Vainchenker,et al.  Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment. , 2006, Blood.

[40]  T. Laín de Lera,et al.  Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  Kohsuke Imai,et al.  Clinical course of patients with WASP gene mutations. , 2004, Blood.

[42]  F. Candotti,et al.  Second-site mutation in the Wiskott-Aldrich syndrome (WAS) protein gene causes somatic mosaicism in two WAS siblings. , 2003, The Journal of clinical investigation.

[43]  K. Schwarz,et al.  Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. , 2003, Pediatrics.

[44]  F. Adam,et al.  Thrombin‐induced platelet PAR4 activation: role of glycoprotein Ib and ADP , 2003, Journal of thrombosis and haemostasis : JTH.

[45]  L. Dupré,et al.  Wiskott-Aldrich syndrome protein regulates lipid raft dynamics during immunological synapse formation. , 2002, Immunity.

[46]  P. Nurden,et al.  Platelet ultrastructural abnormalities in three patients with type 2B von Willebrand disease , 2000, British journal of haematology.

[47]  H. Ochs,et al.  Actin cytoskeletal function is spared, but apoptosis is increased, in WAS patient hematopoietic cells. , 2000, Blood.

[48]  U. Francke,et al.  The Wiskott-Aldrich syndrome and X-linked congenital thrombocytopenia are caused by mutations of the same gene. , 1995, Blood.

[49]  Julia Brasch,et al.  Severity Scoring of Atopic Dermatitis: The SCORAD Index , 1993 .

[50]  V. Kiefel,et al.  Monoclonal antibody--specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. , 1987, Blood.

[51]  E. C. Pielou.  The measurement of diversity in different types of biological collections , 1966 .